medigraphic.com
ISSN 2954-3835 (Digital)
ISSN 2683-2828 (Impreso)

2021, Número S1

<< Anterior

Cardiovasc Metab Sci 2021; 32 (S1)


Primera declaración Mexicana en materia de Insuficiencia Cardiaca

Magaña SJA, Cigarroa LJÁ, Chávez MA, Rayo CJ, Galván OH, Aguilera MLF, Ivey MJB, Rascón SR, Mendez MGF, Mendoza ZGH, Olmos DL, Chávez LS, Olalde RMJ, Fernández MMJ, Aceves GM, Pombo BE, Pacheco BAD, de León LG, Coutiño HE, Mariona MVA, González J, Hernández RE, Álvarez GA, Álvarez ÁRJ, Guízar SCA, Araiza GD, Herrera GEH, Castán FD, Ruiz RVE, Tepayotl AA, Gutiérrez FP, Borrayo SG, Alcocer GMA

Idioma: Inglés [English version]
Referencias bibliográficas: 240
Paginas: 8-85
Archivo PDF: 984.57 Kb.


FRAGMENTO

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Guha K, McDonagh T. Heart failure epidemiology. European perspective. Curr Cardiol Rev. 2013; 9: 123-127.

  2. Virani S, Alonso A, Benjamin E. Heart disease and stroke statistics-2020 update: a report from the American Heart Association. Circulation. 2020; 141: e139-e596.

  3. INEGI Comunicado de prensa núm 538/19. [31 de Octubre de 2019]. En: www.inegi.org.mx

  4. Ponikowski P, Voors A, Anker S, Bueno H, Cleland J, Coats A. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016; 37: 2129-2200.

  5. Davie AP, Francis CM, Love MP, Caruana L, Starkey IR, Shaw TR, Sutherland GR, McMurray JJ. Value of the electrocardiogram in identifying heart failure due to left ventricular systolic dysfunction. BMJ. 1996; 312: 222.

  6. Hindricks G, Potpara T, Dagres N. 2020 ESC Guidelines for the Diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021; 42 (5): 373-498.

  7. Maisel A, Krishnaswamy P, Nowak R. Rapid measurement of b-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002; 347: 161-167.

  8. Brunner-La Rocca H, Sanders-van Wijk S. Natriuretic peptides in chronic heart failure. Cardiac Fail Rev. 2019; 5: 44-49.

  9. Bettencourt P, Azevedo A, Pimenta J, Friões F, Ferreira S, Ferreira A. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation. 2004; 110: 2168-2174.

  10. Nayer J, Aggarwal P, Galwankar S. Utility of point-of-care testing of natriuretic peptides (brain natriuretic peptide and n-terminal pro-brain natriuretic peptide) in the emergency department. Int J Crit Illn Inj Sci. 2014; 4: 209-215.

  11. Latini R, Masson S, Anand IS. Prognostic value of very low plasma concentrations of troponinT in patients with stable chronic heart failure. Circulation. 2007; 116: 1242-1249.

  12. Nieminen M Brutsaert D, Dickstein K. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J. 2006; 27: 2725-2736.

  13. Metra M, Cotter G, Davison B. Effect of Serelaxin on Cardiac, Renal, and Hepatic Biomarkers in the Relaxin in Acte Heart Failure (RELAX-AHF) Development Program. J Am Coll Cardiol. 2013; 61: 196-206.

  14. Jankowska E, Tkaczyszyn M, Drozd M, Ponikowski P. Monitoring of iron statuts in patients with heart failure. Eur Heart J. 2019; 21: M32-M35.

  15. Cigarroa LJ, Magaña SJ, Chávez MA. Manejo del paciente con diabetes e insuficiencia cardiaca. Edit. Springer, 2020.

  16. Magaña SJA, Cigarroa LJA, Maza JG. 50 preguntas clave en insuficiencia cardiaca, Edit. Permanyer México, ISBN 978-84-17221-40-9.

  17. Mitchell C, Rahko P, Blauwet L. Guidelines for performing a comprehensive transthoracic echocardiographic examination in adults: recommendations from the American Society of Echocardiography. J Am Soc Echocardiography. 2019; 32: 1-64.

  18. Aziz W, Claridge S, Ntalas I. Emerging role of cardiac computed tomography in heart failure. ESC Heart Fail. 2019; 6: 909-920.

  19. Habi C, Trieu NH, Saab I, Dangeard S, Bennani S, Chassagnon G, Revel M. COVID-19 pneumonia: a review of typical CT findings and differential diagnosis. Diagn Interv Imaging. 2020; 263-268.

  20. Lles L, Pfluger H, Phrommintikul A. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J Am Coll Cardiol. 2008; 51: 1574-1580.

  21. Mascherbauer J, Marzluf B, Tufaro C. Cardiac magnetic resonance postcontrast T1 time is associated with outcome in patients with heart failure. Circ Cardiovasc Imaging. 2013; 6: 1056-1065.

  22. Yoshida A, Ishibashi-Ueada H, Yamada N. Direct comparison of the diagnostic capability of cardiac magnetic resonance and endomyocardial biopsy in patients with heart failure. Eur J Heart Fail. 2013; 15: 166-175.

  23. Hundley WG, Bluemke DA, Finn JP. ACCF/ACR/AHA/NASCI/SCMR 2010 Expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. J Am Coll Cardiol. 2010; 55: 2614-2662.

  24. Bruder O, Schneider S, Pitz G. 2015 update on acute adverse reactions to gadolinium based contrast agents in cardiovascular MR. Large multi-national and multi-ethnical population experience with 37788 patients from the EuroCMR Registry. J Cardiovasc Magn Reson. 2015; 17: 58.

  25. Obeng-Gylmah E, Nazarian S. Cardiac magnetic resonance as a tool to asses dyssynchrony. Electrophysiol Clin. 2019; 11: 49-53.

  26. Geva T. MRI is the Preferred method for evaluating right ventricle size and function in patients with congenital heart disease. Circ Cardiovasc Imaging. 2014; 7: 190-197.

  27. Valbuena LS, Hinojar R, Puntmann V. Resonancia magnética cardiovascular en la práctica cardiológica: una guía concisa para la adquisición de imágenes y la interpretación clínica. Rev Esp Cardiol. 2016; 69: 202-210.

  28. Wolk M, Bailey S, Doherty J. ACCF/AHA/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2013 multimodality appropriate use criteria for the detection and risk assessment of stable ischemic heart disease: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhytm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2014; 63: 380-406.

  29. Matsuo S, Nakajima K, Kinuya S. Clinical use of nuclear cardiology in the assessment of heart failure. World J Cardiol. 2010; 2: 344-356.

  30. Giannitsi S, Bougiakli M, Bechlioulis A, Kotsia A, Michalis L, Naka K. 6-minute walking test: a useful tool in the management of heart failure patients. Ther Adv Cardiovasc Dis. 2019; 13: 1753944719870084. doi: 10:1177/1753944719870084.

  31. Garin O, Soriano N, Ferrer M. Validación de la versión española del Minnesota Living with Heart Failure Queastionnaire. Rev Esp Cardiol. 2008; 61: 251-259.

  32. Comin-Colet J, Garin O, Lupón J. Validación de la versión española del Kansas City Cardiomyopathy Questinnaire. Rev Esp Cardiol. 2011; 64: 51-58.

  33. EuroQoL Research Foundation. EQ-5D-5L Users Guide, 2019, Available in: https://euroqol.org/publications/user-guides.

  34. Agostini P, Paolillo S, Mapelli M. Multiparametric prognostic scores in chronic heart failure with reduced ejection fraction: a long term comparison. Eur J Heart Fail. 2018; 20: 700-710.

  35. Rich J, Burns J, Feed B. Meta-analysis global group in chronic (MAGGIC) heart failure risk score: validation of a simple tool for the prediction of morbidity and mortality in heart failure with preserved ejection fraction. J Am Heart Assoc. 2018; 7 (20): e009594.

  36. Konerman M, Hummel S. Sodium restriction in heart failure: benefit of harm? Curr Treat Options Cardiovasc Med. 2014; 16: 286.

  37. Doukky R, Avery E, Mangla A. Impact of dietary sodium restriction on heart failure outcomes. JACC Heart Fail. 2016; 4: 24-35.

  38. Yancy C. The uncertainty of sodium restriction in heart failure: we can do better than this. JACC Heart Fail. 2016; 4 (1): 39-41.

  39. DiNicolantonio JJ, Chatterjee S, O’Keefe JH. Dietary salt restricttoon in heart failure: where is the evidence? Prog Cardiovasc Dis. 2016; 58: 401-406.

  40. Levitan EB, Lewis CE, Tinker LF. Mediterranean and DASH diet scores and mortality in women with heart failure: the women’s health initiative. Circ Heart Fail. 2013; 6: 1116-1123.

  41. Ramiro-Ortega E, Bonilla-Palomas JL, Gámez-López AL. Nutritional intervention in acute heart failure patients with undernutrition and normalbuminemia: a subgroup analysis of PICNIC study. Clin Nutr. 2018; 37: 1762-1764.

  42. Fitó M, Estruch R, Salas-Salvadó J. Effect of the Mediterranean diet on heart failure biomarkers: a randomized sample from the PREDIMED trial. Eur J Heart Fail. 2014; 16: 543-550.

  43. Abshire M, Xu J, Baptiste D. Nutritional interventions in heart failure: a systematic review of the literature. J Card Fail. 2015; 21: 989-999.

  44. Oga EA, Eseyin OR. The obesity paradox and heart failure: a systematic review of a decade of evidence. J Obes. 2016; 2016: 9040248.

  45. Li Y, Fu B, Qian X. Liberal versus restricted fluid administration in heart failure patients: a systematic review and meta-analysis of randomized trials. Int Heart J. 2015; 56: 192-195.

  46. Aggaewai M, Bozkurt B, Panjrath B. Lifestyle modifications for preventing and treating heart failure. J Am Coll Cardiol. 2018; 72: 2391-2405.

  47. Klempfner R, Tzur B, Sabbaq A. Participation in an exercise-based cardiac rehabilitation program and functional improvement of heart failure patients with preserved versus reduced left ventricular systolic function. Isr Med Assoc J. 2018; 20 (6): 358-362.

  48. Hamad AA, Sauer LAo, Dougherty CM. A systematic review of exercise training in cardiac implantable devices. J Cardiopulm Rehabil Prev. 2018; 38 (2): 70-84.

  49. Yardley M, Gullestad L, Nytroen K. Importance of physical capacity and the effects of exercise in heart transplant recipients. World J Transplant. 2018; 8 (1): 1-12.

  50. Mediano MFF, Leifer ES, Cooper LS. Influence of baseline physical activity level on exercise training response and clinical outcomes in heart failure: the HF-ACTION trial. JACC Heart Fail. 2018; 6: 1011-1019.

  51. Cattadori G, Segurini C, Picozzi A, Padeletti L, Anza C. Exercise and Heart Failure: an update. ESC Heart Fail. 2018; 5: 222-232.

  52. Wallenborn J, Angermann CE. Comorbid depression in heart failure. Herz. 2013; 38: 587-596.

  53. Jeyanantham K, Kotecha D, Thanki D, Dekker R, Lane DA. Effects of cognitive behavioural therapy for depression in heart failure patients: a systemic review and meta-analysis. Heart Fail Rev. 2017; 22: 731-741.

  54. Celano CM, Villegas AC, Albanese AM, Gaggin HK, Huffman JC. Depression and anxiety in heart failure: a review. Harv Rev Psychiatry. 2018; 26: 175-184.

  55. Albano MG, Jourdain P, DE Andrade V, Domenke A, Desnos M, dÍvernois JF. Therapeutic patient education in heart failure: do studies provide sufficient information about the educational programme? Arch Cardiovasc Dis. 2014; 107: 328-339.

  56. Vaillant-Roussel H, Laporte C, Pereira B. Patient education in chronic heart failure in primary care (ETIC) and its impact on patient quality of life: design of a cluster randomized trial. BMC Fam Pract 2014; 15: 208. doi: 10.1186/s12875-014-0208-3.

  57. Park LG, Dracup K, Whooley MA. Symptom dietary use and improved survival for patients with heart failure. Circ Heart Fail. 2017; 10 (11): e003874. doi: 10.1161/CIRCHEARTFAILURE.117.003874.

  58. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987; 316: 1429-1435.

  59. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992; 327: 685-691.

  60. Pitt B, Poole-Wilson PA, Segal R. Effect of losartan compared with captropril on mortality in patients with symptomatic heart failure: randomized trial- the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000; 355: 1582-1587.

  61. Solomon SD, Anavekar N, Skali H. Candesartan in Heart Failure Reduction in Mortality (CHARM) Investigators. Candesartan in Heart Failure Reduction in Mortality (CHARM) Investigators. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation. 2005; 112: 3738-3744.

  62. Maggioni AP, Anand I, Gottlieb SO. Val-HeFT Investigators (Valsartan Heart Failure Trial). Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin converting enzyme inhibitors. J Am Coll Cardiol. 2002; 40: 1414-1421.

  63. Heran BS, Musini VM, Bassett K, Taylor RS and wright JM. Angiotensin receptor blockers for heart failure. Cochrane Database Syst Rev. 2012; 4: CD003040.

  64. Pardeep S, McMurray J. The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan. Heart. 2016; 102: 1342-1347.

  65. McMurray JJV, Packer M, Desai AS. PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014; 371: 993-1004.

  66. Desai A, McMurray J, Packer M. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J. 2015; 36: 1990-1997.

  67. Wachter R, Senni M, Belohlavek J. Initiation of sacubitril/valsartan in haemodynamically stabilized heart failure patients in hospital or early after discharge: primary results of the randomized TRANSITION study. Eur J Heart Fail. 2019; 21: 998-1007.

  68. Velázquez EJ, Morrow A, DeVore AD. Rationale and design of the comparison Of sacubitril/valsartan versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial. Am Heart J. 2018; 198: 145-151.

  69. Morrow DA, Velázquez EF, DeVore AD. Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial. Eur Heart J. 2019; 40: 3345-3352.

  70. Willenheimer R, Van Veldhuisen DJ, Silke B, Erdmann E, Follath F, Krum H et al. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insuf-ciency Bisoprolol Study (CIBIS) III. Circulation. 2005; 112: 2426-2435.

  71. Packer M. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the Carvedilol Prospective Randomized Cumulative Sur- vival (COPERNICUS) Study. Circulation- 2002; 106: 2194-2199.

  72. Hjalmarson A, Goldstein S, Fagerberg B. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well- being in patients with heart failure: the metoprolol CR/XL Randomized Intervention Trial in congestive Heart Failure (MERIT-HF). MERIT-HF Study Group. JAMA. 2000; 283 (10): 1295-1302.

  73. Frolich H, Torres L, Tager T. Bisoprolol compared with carvedilol and metoprolol succinate in the treatment of patients with chronic heart failure. Clin Res Cardiol. 2017; 106: 711-721.

  74. Choi KH, Lee GY, Choi JO. The mortality benefit of Carvedilol versus bisoprolol in patients with heart failure with reduced ejection fraction. Korean J Intern Med. 2019; 34: 1030-1039.

  75. Tsutsui H, Momomura Sh, Masuyama T. Tolerability, efficacy, and safety of bisoprolol vs. carvedilol in Japanese patients with heart failure and reduced ejection fraction- The CIBIS- J Trial. Circ J 2019; 83: 1269-1277.

  76. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999; 341: 709-717.

  77. Zannad F, McMurray JJV, Krum H, Van Veldhuisen DJ, Swedberg K, Shi H et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011; 364: 11-21.

  78. Zimman B, Wanner C, Lachin JM. Empagliflozin, cardiovascular outcomes and mortality in type 2 diabetes. N Engl J Med. 2015; 373: 2117-2128.

  79. Neal B, Perkovic V, Mahaffey KW. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017; 377: 644-657.

  80. Wiviott SD, Raz I, Bonaca MP. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019; 380: 347-357.

  81. McMurray J, Solomon S, Izucchi S. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019; 381: 1995-2008.

  82. Packer M, Anker S, Butler J. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020; 383 (15): 1413-1424. doi: 10.1056/NEJMoa2022190.

  83. Mullens W, Damman K, Harjola VP. The use of diuretics in heart failure with congestion – a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019; 21: 137-155.

  84. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997; 336: 525-533.

  85. Bavishi C, Khan AR, Ather S. Digoxin in patients with atrial fibrillation and heart failure: a meta-analysis. Int J Cardiol. 2015; 188: 99-101.

  86. Scalese MJ, Salvatore DJ. Role of digoxin In atrial fibrillation. J Pharm Pract. 2017; 30 (4): 434-440.

  87. Formiga F, Ariza A. Digoxin in reduced heart failure and sinus rhytm. When should it be indicated in 2018; Rev Esp Geriatr Gerontol. 2018; 53: 119-120.

  88. Bohm M, Swedberg K, Komajda M. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomized placebo controlled trial. Lancet. 2010; 376: 886-894.

  89. Zhou Y, Wang J, Meng Z. Phramacology of ivabradine and the effect on chronic heart failure. Curr Top Med Chem. 2019; 19: 1878-1901.

  90. Swedberg K, Komajda M, Bohm M. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomized placebo-controlled study. Lancet. 2010; 376: 875-885.

  91. Al-Mohammad A. Hydralazine and nitrates in the treatment of heart failure with reduced ejection fraction. ESC Heart Fail. 2019; 6: 878-883.

  92. Ziaeian B, Fonarow G, Heidenreich PA. Clinical effectiveness of hydralazine-isosorbide dinitrate in African-american patients with heart failure. JACC Heart Fail. 2017; 5: 632-639.

  93. Zeitler E, Zubin JE. Anticoagulation in heart failure: a review. J Atr Fibrillation. 2015; 8: 1250.

  94. Homma S, Thompson JL, Pullicino PM. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med. 2012; 366: 1859-1869.

  95. Lip GY, Shantsila E. Anticoagulation versus placebo for heart failure in sinus rhythm. Cochrane Database Syst Rev. 2014; (3): CD003336. doi: 10.1002/14651858.CD003336.pub3.

  96. Komajda M, Bohm M, Borer J. Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysis. Eur J Heart Fail. 2018; 2: 1315-1322.

  97. Greene SJ, Butler J, Albert N. Medical therapy for heart failure with reduced ejection fraction. The CHAMP-HF registry. J Am Coll Cardiol. 2018; 72: 351-366.

  98. Butler J, Yang M, Manzi M. Clinical course of patients with worsening heart failure with reduced ejection fraction. J Am Coll Cardiol. 2019; 73: 935-944.

  99. Chen LY, Chung MK, Allen LA. Atrial fibrillation burden: moving beyond atrial fibrillation as a binary entity. A scientific statement from the American Heart Association. Circulation. 2018; 137: e623-e644.

  100. Lip GY, Nieuwlaat R, Lane D, Crijns H. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010; 137: 263-272.

  101. Piccini J, Fauchier L. Rhythm control in atrial fibrillation. Lancet. 2016; 388: 829-840.

  102. Van Gelder I, Rienstra M, Crijns H, Olshansky B. Rate control in atrial fibrillation. Lancet. 2016; 388: 818-828.

  103. Marrouche NF, Brachmann J, Andressen D. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med. 2018; 378: 417-427.

  104. Mansour M, Cakins H, Osorio J. Persistent atrial fibrillation ablation with contact force-sensing catheter. The prospective multicenter PRECEPT trial. J Am Coll Cardiol. 2020; 6: 958-969.

  105. Steinberg B, Mulpuru S, Fang J, Gersh B. Sudden death mechanisms in nonischemic cardiomyopathies: insights gleaned from clinical implantable cardioverter-defibrillator trials. Heart Rhythm. 2017; 14: 1839-1848.

  106. Li Shen MB, Pardeep SJ, Petrie MC. Declining risk of sudden death in heart failure. N Engl J Med. 2017; 377: 41-51.

  107. El-Battrawy I, Borggrefe M, Akin I. The risk of sudden cardiac death and effect of treatment with sacubitril/valsartan in heart failure. JACC Heart Fail. 2019; 7: 457-465.

  108. Yung D, Birnie D, Dorian P. Survival after implantable cardioverter-defibrillator implantation in the elderly. Circulation. 2013; 127: 2383-2392.

  109. Hess PL, Al-Khati SM, Han JY. Survival benefit of the primary prevention implantable cardioverter-defibrillator among older patients: does age matter? An analysis of pooled data from 5 clinical trials. Circ Cardiovasc Qual Outcomes. 2015; 8: 179-186.

  110. Elming M, Nielsen JC,Haarbo J. Age and outcomes of primary prevention implantable cardioverter-defibrillators in patients with nonischemic systolic heart failure. Circulation. 2017; 136: 1772-1780.

  111. Pun PH, Smarz TR, Honeycutt EF, Shaw LK, Al-Khatib SM, Middleton JP. Chronic kidney disease is associated with increased risk of sudden cardiac death among patients with coronary artery disease. Kidney Int. 2009; 76: 652-658.

  112. Jadoul M, Thumma J, Fuller DS. Modifiable practices associated with sudden death among hemodialysis patients in the dialysis outcomes and practice patterns study. Clin J Am Soc Nephrol. 2012; 7: 765-774.

  113. Jukema JW, Timal RJ, Rotmans JI. Prophylactic Use of Implantable cardioverter-defibrillators in the prevention of sudden cardiac death in dialysis patients. Circulation. 2019; 139: 2628-2638.

  114. Roberts PR, Zachariah D, Morgan JM. Monitoring of arrhythmia and sudden death in a hemodialysis population: The CRASH-ILR Study. PLoS One. 2017; 12: e0188713.

  115. Pun PH, Al-Khatib SM, Han JY. Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death in CKD: a meta-analysis of patient-level data from 3 randomized trials. Am J Kidney Dis. 2014; 64 (1): 32-39.

  116. Bansal N, Szpiro A, Reynolds K. Long-term outcomes associated with implantable cardioverter defibrillator in adults with chronic kidney disease. JAMA Intern Med. 2018; 178 (3): 390-398.

  117. Menozzi C, Brignole M, García-Civera R. Mechanism of syncope in patients with heart disease and negative electrophysiologic test. Circulation. 2002; 105: 2741-2745.

  118. Elming MB, Hammer-Hansen S, Voges I. Myocardial fibrosis and the effect of primary prophylactic defibrillator implantation in patients with non-ischemic systolic heart failure-DANISH-MRI. Am Heart J. 2020; 221: 165-176.

  119. Halliday BP, Gulati A, Ali A. Association between midwall late gadolinium enhancement and sudden cardiac death in patients with dilated cardiomyopathy and mild and moderate left ventricular systolic dysfunction. Circulation. 2017; 135: 2106-2115.

  120. Selvanayagam JB, Hartshorne T, Billot L. Cardiovascular magnetic resonance-GUIDEd management of mild to moderate left ventricular systolic dysfunction (CMR GUIDE): Study protocol for a randomized controlled trial. Ann Noninvasive Electrocardiol. 2017; 22: e12420.

  121. Sapp JL, Wells GA, Parkash R. Ventricular Tachycardia Ablation versus escalation of antiarrhythmic drugs. N Engl J Med. 2016; 375: 111-121.

  122. Bleeker GB, Bax JJ, Steendijk P, Schaliij MJ, van der Wall EE. Left ventricular dyssynchrony in patients with heart failure: pathophysiology diagnosis and treatment. Nat Clin Pract Cardiovasc Med. 2005; 3: 213-219.

  123. Tayal B, Sogaard P, Risum N. Why dyssynchrony matters in heart failure. Card Electrophysiol Clin. 2019; 11: 39-47.

  124. Khidir MJ, Delgado V, Ajmone M. Mechanical dyssynchrony in patients with heart failure and reduced ejection fraction: how to measure? Curr Opin Cardiol. 2016; 31: 523-530.

  125. Cleland JG, Abraham WT, Linde C. An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J. 2013; 34: 3547-3556.

  126. Linde C, Gold MR, Abraham WT, St John Sutton M, Ghio S, Cerkvenik J, Daubert C. Long-term impact of cardiac resynchronization therapy in mild heart failure: 5-year results from the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study. Eur Heart J. 2013; 34: 2592-2599.

  127. Pitzalis MV, Iacoviello M, Romito R. Ventricular asynchrony predicts a better outcome in patients with chronic heart failure receiving cardiac resynchronization therapy. J Am Coll Cardiol. 2005; 45: 65-69.

  128. Rickard J, Kumbhani DJ, Popovic Z. Characterization of super-response to cardiac resynchronization therapy. Heart Rhythm. 2010; 7: 885-889.

  129. Mollema SA, Bleeker GB, van der Wall EE, Schalij MJ, Bax JJ. Usefulness of QRS duration to predict response to cardiac resynchronization therapy in patients with end-stage heart failure. Am J Cardiol. 2007; 100: 1665-1670.

  130. Ruschitzka F, Abraham WT, Singh JP. Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med. 2013; 369: 1395-1405.

  131. Tian Y, Zhang P, Li X. True complete left bundle branch block morphology strongly predicts good response to cardiac resynchronization therapy. Europace. 2013; 15: 1499-1506.

  132. Barold S, Herweg B. Cardiac resynchronization in patients with atrial fibrillation. J Atr Fibrillation. 2015; 8: 1383-1393.

  133. Conrad N, Judge A, Tran J. Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. Lancet. 2018; 391: 571-580.

  134. Messerli F, Rimoldi S, Bangalore S. The transition from hypertension to heart failure. contemporary update. JACC Heart Fail. 2017; 5: 543-551.

  135. Magaña SJ. Hipertensión arterial y sus complicaciones: insuficiencia cardiaca, fibrilación auricular y enfermedad cerebrovascular. En: Ávila VN. 100 preguntas clave en hipertensión arterial. Edit. Permanyer México 2020, pp. 57-65. iSBN: 978-84-1850-12.8.

  136. Pinho-Gomes A, Rahimi K. Management of blood pressure in heart failure. Heart. 2019; 105: 589-595.

  137. Kjeldesen SE, von Lueder TG, Smiseth OA. Medical therapies for heart failure with preserved ejection fraction. Hypertension. 2020; 75: 23-32.

  138. Nichols GA, Gullion CM, Koro CE. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care. 2004; 27: 1879-1884.

  139. Johansson I, Dahlstrom U, Edner M. Prognostic implications of type 2 Diabetes mellitus in ischemic and nonischemic heart failure. J Am Coll Cardiol. 2016; 68: 1404-1416.

  140. Kristensen S, Preiss D, for the PARADIGM-HF Investigators and Committess. Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction. Insights from prospective comparison or ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial. Circ Heart Fail. 2016; 9: e002560.

  141. Lercke M, Marx N. Diabetes mellitus and heart failure. Am J Med. 2017; 130: S40-S50.

  142. Kenny HC, Abel ED. Heart failure in type 2 diabetes mellitus. Circ Res. 2019; 124: 121-141.

  143. Cigarroa JA, Magaña SJ, Chávez MA. Manejo del paciente con diabetes e Insuficiencia. Cardiaca. Edit. Springer México, 2020. ISBN 978-607-98663-9-6.

  144. Cosentino F, Grant PJ, Aboyans V. 2019 ESC Guidelines on Diabetes, pre-diabetes and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020; 41: 255-323.

  145. Standards of Medical Care in Diabetes-2019. Diabetes Care. 2019; 42 (Suppl.1): S1-S204.

  146. Martens P, Mathieu C, Verbrugge FH. Promise of SGLT2 inhibitors in heart failure: diabetes and beyond. Curr Treat Options Cardio Med. 2017; 19: 23.

  147. Scheen AJ. GLP-1 receptor agonists and heart failure in diabetes. Diabetes Metab. 2017; 43: 2513-2519.

  148. Anand IS. Anemia and iron deficiency in heart failure. Current concepts and emerging therapies. Circulation. 2018; 138: 80-98.

  149. Rocha ML, Cunha G, Menezes L. The burden of iron deficiency in heart failure: therapeutic approach. J Am Coll Cardiol. 2018; 71: 782-793.

  150. Jankowska E, Tkaczyszyn M, Suchocki T. Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials. Eur J Heart Fail. 2016; 18: 786-795.

  151. Seferovic P, Ponikowski P, Anker S. Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019; 21: 1169-1186.

  152. Anker SD, Comin CJ, Filippatos G. FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009; 361: 2436-2448.

  153. Ponikowski P, van Veldhuisen DJ, Comín CJ. CONFIR;-HF Investigators. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J. 2015; 36: 657-668.

  154. Carbone S, Canada J, Billinsgley H. Obesity paradox in cardiovascular disease: where do we stand? Vasc Health Risk Manag. 2019; 15: 89-100.

  155. Lewis GA, Schelbert E, Williams S. Biological phenotypes of Heart Failure with Preserved Ejection Fraction. J Am Coll Cardiol. 2017; 70: 2186-2200.

  156. Reddy YNV, Anantha-Narayanan M, Obokata M. Hemodynamic effects of weight loss in obesity. J Am Coll Cardiol HF. 2019; 7: 678-687.

  157. Lavie CJ, Ventura HO, The obesity paradox in heart failure: is it all about fitness, fat, or sex? J Am Coll Cardiol HF. 2015; 3: 927-930.

  158. Heywood JT, Fonarow GC, Constanzo MR. ADHERE Scientific Advisory Committee and Investigators. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail. 2007; 13: 422-430.

  159. Preeti J, Mebazaa A, Ivngkaran P. Chronic heart failure and comorbid renal dysfunction- a focus on type 2 cardiorenal syndrome. Curr Cardiol Rev. 2016; 12: 186-194.

  160. Braunwald E. Diabetes, heart failure and renal dysfunction: the vicious circles. Porg Cardiovasc Dis. 2019; 62: 298-302.

  161. Sarli IV, Andrade L, Bocchi EA. Current strategies for preventing renal dysfunction in patients with heart failure: a heart failure stage approach. Clinics (Sao Paulo). 2013; 68: 401-409.

  162. Raina R, Nair N, Chakraborty R, Nemer L, Dasgupta R, Varian K. An update on the pathophysiology and treatment of cardiorenal syndrome. Cardiol Res. 2020; 11: 76-88.

  163. Neumman FJ, Sousa M, Ahlsson A. 2018 ESC/EACT Guidelines on myocardial revascularization. Eur Heart J. 2019; 40: 87-165.

  164. Velazquez EJ, Lee KL, Deja MA. STICH Investigators. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med. 2011; 364: 1607-1616.

  165. Stone GW, Lindefeld J, Abrham WT. COAPT Investigators. Transcatheter mitral valve repair in patients with heart failure. N Engl J Med. 2018; 379: 2307-2318.

  166. Obadia JF, Messika-Zeitoun D, Leurent G. MITRA-FR Investigators. Percutaneous repair or medical treatment for secondary mitral regurgitation. N Engl J Med. 2018; 379: 2297-2306.

  167. Fischer RU, Renker M, Liebetrau Ch. Outcome of patients with heart failure after transcatheter aortic valve implantation. PLOS ONE. 2019; 14: e0225473.

  168. Kurmani S, Squire I. Acute heart failure: definition, classification and epidemiology. Curr Heart Fail Rep. 2017; 14: 385-392.

  169. Arrigo M, Ruschitzka F, Flammer AJ. Acute heart failure. Ther Umsch. 2018; 75: 155-160.

  170. Long B, Koyfman A, Gottleib M. Management of heart failure in the emergency department: an evidence based review of the literature, J Emerg Med. 2018; 55: 635-646.

  171. Chioncel O, Mebazaa A, Harjola V. Clinical phenotypes and outcome of patients hospitalized for acute heart failure: The ESC heart failure long-term registry. Eur J Heart Fail. 2017; 19: 1242-1254.

  172. González PH, Álvarez SgA, Martínez SC. Clinical phenotypes, aetiologies, management, and mortality in acute heart failure: a single-institution study in Latin-America. ESC Heart Fail. 2020; 8 (1): 423-437. doi: 10.1002/ehf2.13092.

  173. Abdo AS. Hospital management of acute decompensated heart failure. Am J Med Sci. 2017; 353: 265-274.

  174. Dandamudi S, Chen HH. The ASCEND-HF Trial: an acute study of clinical effectiveness of nesiritide and decompensated heart failure. Expert Rev Cardiovasc Ther. 2012; 1: 557-563.

  175. Packer M, Colucci W, Fisher L. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC Heart Fail. 2013; 1 (2): 103-111.

  176. Mebazaa A, Nieminen MS, Packer M. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA. 2007; 297: 1883-1891.

  177. Ghosh RK, Banerjee K, Tummala R, Ball S, Ravakhah K, Gupta A. Serelaxin in acute heart failure: most recent update on clinical and preclinical evidence. Cardiovasc Ther. 2017; 35: 55-63.

  178. Felker G, Mentz R, Cole R. Efficacy and safety of tolvaptan in patients hospitalized with acute heart failure. J Am Coll Cardiol. 2017; 69: 1399-1406.

  179. Davidson BA, Metra M, Cotter G. Worsening heart failure following admission for acute heart failure: a pooled analysis on the PROTECT and RELAX-AHF studies. JACC Heart Fail. 2015; 3: 395-403.

  180. Greene SJ, Fonarow GC, Vaduganathan M, Khan SS, Butler J, Gheorgiade M. The vulnerable phase after hospitalization for heart failure. Nat Rev Cardiol. 2015; 12: 220-229.

  181. Cowie M, Lopatin Y, Saldarriaga C, Fonseca C, Sim D, Magaña JA et al. The optimize heart failure care program: initial lessons from global implementation. Int J Cardiol. 2017; 236: 340-344.

  182. Crespo-Leiro MG, Metra M, Lund LH. Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018; 20: 1505-1535.

  183. Felker GM, Ellison DH, Mullens W, Cox ZL, Testani JM. Diuretic therapy for patients with heart failure: JACC state of art review. J Am Coll Cardiol. 2020; 75: 1178-1195.

  184. Comin-Colet J, Manito N, Segovia-Cubero J. LION-HEART Study investigators. Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomized trial. Eur J Heart Fail. 2018; 20: 1128-1136.

  185. Silvetti S, Belletti A, Fontana A, Pollesello P. Rehospitalization after intermittent levosimendan treatment in advanced heart failure patients: a meta analysis of randomized trials. ESC Heart Fail. 2017; 4: 595-604.

  186. Stevenson LW, Pagani FD, Young JB. INTERMACS profiles of advanced heart failure: the current picture. J Heart Lung Transplan. 2009; 28: 535-541.

  187. Feldman D, Pamboukian SV, Teuteberg JJ. The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: executive summary. J Heart Lung Transplant. 2013; 32: 157-187.

  188. Combes A. Mechanical circulatory support for end-stage heart failure. Metabolism. 2017; 69S: S30-S35.

  189. Canepa M, Fonseca C, Chioncel O. Performance of prognostic risk scores in chronic heart failure enrolled in the European society of cardiology heart failure long-term registry. JACC Heart Fail. 2018; 6: 452-462.

  190. Mehra M. Guidelines for listing candidates for heart transplant: a 10-year Update. JAMA Cardiol. 2017; 2: 98-99.

  191. Rabin J, Kaczorowski D. Perioperative management of the cardiac transplant recipient. Crit Care Clin. 2019; 35: 45-60.

  192. International Thoracic Organ Transplant (TTX) Registry. Overall Heart Transplantation Statistics. Downloaded from: www.ishltregistries.org.

  193. Rogers J, Patei Ch, Mentz R. The palliative care in heart failure (PAL-HF) randomized, controlled clinical trial. J Am Coll Cardiol. 2017; 70: 331-341.

  194. O’Donnell A, Schaefer K, Stevenson L. Social worker-aided palliative care intervention in high-risk patients with heart failure (SWAP-HF): a pilot randomized clinical trial. JAMA Cardiol. 2018; 3: 516-519.

  195. Magaña SJ, Almahmeed W, Gómez E. Prevalence of Heart Failure With Preserved Ejection Fraction in Latin American, Middle Eastern and North African Regions in the I PREFER Study (Identification of patients With Heart Failure and PREserved Systolic Function: An Epidemiological Regional Study). Am J Cardiol. 2011; 108: 1289-1296.

  196. Magaña SJ, Rosas PM, Candanosa AC. Insuficiencia cardiaca con fracción de expulsión preservada. Impacto del cambio en el paradigma de la disfunción diastólica aislada. Gac Méd Méx. 2015; 151: 635-647.

  197. Pieske B, Tschope C, de Boer R. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology. Eur Heart J. 2019; 40: 3297-3317.

  198. Shah S, Kitzman D, Bourlag B. Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap. Circulation. 2016; 134: 73-90.

  199. Pfeffer M, Ciagetti B, Assmann F. Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with aldosterone antagonist (TOPCAT) trial. Circulation. 2015; 131: 34-42.

  200. Cohen J, Schrauben S, Zhao L. Clinical phenogroups in heart failure with preserved ejection fraction. Detailed phenotypes, prognosis, and response to spironolactone. JACC Heart Fail. 2020; 8: 172-184.

  201. Solomon S, McMurray J, Anand I. Angiotension-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019; 381: 609-620.

  202. Sarma S, Stoller D, Hendrix J. Mechanisms of chronotropic incompetence in heart failure with preserved ejection fraction. Circulation Heart Fail. 2020; 13: e006331.

  203. Rattka M, Pott A, Kuhberger A. Restoration of sinus rhythm by pulmonary vein isolation improves heart failure with preserved ejection fraction in atrial fibrillation patients. Europace. 2020; 22: 1328-1336.

  204. Bocchi EA. Heart Failure in South America. Curr Cardiol Rev. 2013; 9: 147-156.

  205. America L. Weekly epidemiological record Relevé épidémiologique hebdomadaire. 2015; (6): 5-13.

  206. Higuchi ML, Benvenuti LA, Martins-Reis M, Metzger M. Pathophysiology of the heart in Chagas’disease:current status and new developments. Cardiovasc Res. 2003; 60: 96-107.

  207. Chaves AT, Menezes CAS, Costa HS, Nunes MCP, Rocha MOC. Myocardial fibrosis in Chagas disease and molecules related to fibrosis. Parasite Immunol. 2019; 41: e12663. doi: 10.1111/plm.12663.

  208. Lee BY, Bacon KM, Bottazzi ME, Hotez PJ. Global economic burden of Chagas disease: a computational simulation model. Lancet infect Dis. 2013; 13: 342-348.

  209. Olivera MJ, Buitrago G. Economic costs of Chagas disease in Colombia in 2017: A social perspective. Int J Infect Dis. 2020; 91: 196-201.

  210. Marcolino MS, Palhares DM, Ferreira LR, Ribeiro A. Electrocardiogram and Chagas disease a large population database of primary care patients. Global Heart. 2015; 10: 167-172. Available in: https://doi.org/10.1016/j.gheart.2015.07.001.

  211. Lunardi AL, Lombardi F, da Costa-Rocha O. Chronotropic incompetence and abnormal autonomic modulation in ambulatory Chagas disease patients. Ann Noninvasive Electrocardiol. 2006; 11: 3-11.

  212. Pérez-Molina JA. Chagas disease. The Lancet. 2017; 673: 1-13. https://doi.org/10.1016/S0140-6736(17)31612-4.

  213. México, G. de A. para enfermedad de C. (2019). Manual de procedimientos para la enfermedad de Chagas en México. Secretaría De Salud, 1-109. Recuperado desde: https://www.gob.mx/cms/uploads/attachment/file/447946/Manual_de_Procedimientos_para_la_Enfermedad_de_Chagas_en_Mexico.pdf.

  214. Organización Panamericana de la Salud. (2018). Guía para el diagnostico y el tratamiento de la enfermedad de Chagas. Washington.

  215. García A, Sitges M, Regueiro M. Myocardial deformation analysis in Chagas heart disease with the use of speckle tracking echocardiography. J Card Fail. 2011; 17: 1028-1034. Available in: https://doi.org/10.1016/j.cardfail.2011.08.007.

  216. Healy C, Viles GJ, Sáenz L. Arrhythmias in Chagasic cardiomyopathy. Cardiac Electrophysiology Clinics. 2015; 7: 251-268.

  217. Andrade J, Marin JA, Paola A. I Latin American guidelines for the diagnosis and treatment of Chagas disease. Arq Bras. 2011; 97 (Suppl) 3: 1-38.

  218. Morillo CA, Marin-Neto JA, Avezum A. Randomized trial of benznidazole for chronic Chagas’ cardiomyopathy. N Engl J Med. 2015; 373: 1295-1306.

  219. Bestetti RB, Theodoropoulos TA, Cardinalli-Neto A, Cury PM. Treatment of chronic systolic heart failure secondary to Chagas heart disease in the current era of heart failure therapy. Am Heart J. 2008; 156: 422-430.

  220. Nunes MC, Beaton A, Acquatella H. Chagas cardiomyopathy: an update of current clinical knowledge and management: a scientific statement from the American Heart Association. Circulation. 2018; 138 (12): e169-e209. Available in: https://doi.org/10.1161/CIR.0000000000000599.

  221. Gilstrao L, Dominici F, Wang Y. Epidemiology of cardiac amyloidosis-associated heart failure hospitalizations among fee-for-service medicare beneficiaries in the United States. Cir Heart Fail. 2019; 12 (6): e005407. Available in: https://doi.org/10.1161/CIRCHEARTFAILURE.118.005407.

  222. Bhogal S, Ladia V, Sitwala P. Cardiac amyloidosis: an updated review with emphasis on diagnosis and future directions. Curr Probl Cardiol. 2018; 43: 10-34.

  223. González-López E, López-Sainz A, García-Pavia P. Diagnosis and treatment of transthyretin cardiac amyloidosis. Progress and Hope. Rev Esp Cardiol. 2017; 70: 991-1004.

  224. Kittleson M, Maurer MS, Ambardekar A. Cardiac amyloidosis. Evolving diagnosis and management: a scientific statement from the American Heart Association. Circulation. 2020; 142: e7-e22.

  225. Perlini S, Mussinelli R, Salinaro F. New and evolving concepts regarding the prognosis and treatment of cardiac amyloidosis. Curr Heart Fail Rep. 2016; 13: 267-272.

  226. Gilstrap G, Niehaus E, Malhotra R. Predictors of survival to orthotopic heart transplant in patients with light chain amyloidosis. J Heart Lung Transplant. 2014; 33: 149-156.

  227. Nishiga M, Wen-Wang D, Han Y, Lewis DB, Wu JC. COVID-19 and cardiovascular disease: from basic mechanism to clinical perspectives. Nature rev Cardiol. 2020; 17: 543-558.

  228. Cigarroa LJ, Magaña SJ, Chávez MA. Recomendaciones para la atención de pacientes con insuficiencia cardiaca y COVID-19. Arch Cardiol Mex. 2020; 90 (Suppl): 26-32.

  229. Principales causas de mortalidad en México. Recuperado de: www.inegi.org.mx.

  230. Zamorano JL, Lancelloti P, Rodríguez MD. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur Heart J. 2016; 37: 2768-2801.

  231. Virani S, Dent S, Brezden-Masley CH. Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy. Can J Cardiol. 2016; 32: 831-841.

  232. Curigliano G, Lenihan D, Fradley M. Management of cardiac disease in cancer patients throughout treatment: ESMO consensus recommendations. Ann Oncology. 2020; 31: 171-190.

  233. Henry M, Niu J, Zhang N, Giordano SH, Chávez-McGregor M. Cardiotoxicity and Cardiac Monitoring Among Chemotherapy-Treated Breast Cancer Patients. JACC Cardiovasc Imaging. 2018; 11: 1084-1093.

  234. Sawaya H, Sebag IA, Plana JC. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging. 2012; 5: 596-603.

  235. Kalam K, Marwick TH. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis. Eur J Cancer. 2013; 49: 2900-2909.

  236. Garrido GM, Magaña SJ, Gaxiola AA. Futuro de las clínicas de insuficiencia cardiaca. En: Clínicas Mexicanas de Cardiología: Insuficiencia Cardiaca. México: Edit. PyDesa; 2011. p. 161-184.

  237. Anguita SM. Programas de intervención en la insuficiencia cardiaca: análisis crítico. Rev Esp Cardiol. 2007; 7: 45-56.

  238. Ponikowski P, Anker S, Alhabib K. Heart Failure. Preventing disease and death worldwide. The Global Heart Failure Awareness Programme. European Society of Cardiology/Heart Failure Association of the ESC; 2014. p. 1-35.

  239. Maru S, Byrnes J, Carrington MJ. Economic evaluation of a nurse-led home and clinic-based secondary prevention programme to prevent progressive cardiac dysfunction in high risk individuals: The Nurse-led intervention for Less Chronic Heart Failure (NIL-CHF) randomized controlled study. Eur J Cardiovasc Nurs. 2018; 17 (5): 439-445.

  240. Saldarriaga C, Garcés JJ, Agudelo A, Guarín L, Mejía J. Impacto clínico de un programa de falla cardiaca. Rev Colomb Cardiol. 2016; 23: 260-267.




2020     |     www.medigraphic.com